You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
"Best Provider" Winner,
2019 Waters Rankings Awards:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
IRDAI approves Max India's stake divestment in Max Bupa
Infrastructure Issues: Tools to Dig Deep on Potential Risks
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Part Two IFRS 9 Blog Series: The Need to Upgrade Analytical Tools
The Insurance Regulatory and Development Authority of India approved True North Fund VI LLP's purchase of Max India Ltd.'s 51% stake in Max Bupa Health Insurance Co. Ltd.
Max India announced the all-cash transaction in February. The acquisition, which is now set to close within the next few weeks, valued Max Bupa at an enterprise value of 10.01 billion rupees.
Max Bupa is a joint venture between U.K.-based Bupa and Max India.
As of Dec. 2, US$1 was equivalent to 71.66 Indian rupees.